There's a new 'game-changing' Rx for psoriasis: What rheums need to know for the clinic

On March 18, 2026, the FDA approved icotrokinra, branded as Icotyde, for adults and adolescents age 12 and older, at least 40 kg, with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug is the first oral targeted peptide to block the IL-23 receptor.^[]

Why does this approval stand out in a crowded field? 

For rheumatologists, this approval matters because psoriatic arthritis develops in up to 30% of patients with psoriasis, and delayed recognition still drives avoidable structural damage.

In the Phase 3 ICONIC-LEAD trial, 65% of icotrokinra-treated patients reached clear or almost clear skin at week 16, vs 8% with placebo. PASI 90 rates were 50% vs 4%.^[] In the Phase 3 ICONIC-ADVANCE 1 and 2 trials, icotrokinra also outperformed placebo and the oral TYK2 inhibitor deucravacitinib.^[][] At week 16, PASI 90 responses were 55% and 57% with icotrokinra, vs 4% and 1% with placebo. Adverse event rates through week 24 were lower with icotrokinra than with deucravacitinib in those studies.

In a post-approval interview, Linda Stein Gold, MD, who worked on the program, put the clinical gap in plain terms: “We have great biologic agents, we have good topical agents, but the oral space really needed something that had very good efficacy, very good safety, and very good tolerability. So I think that this drug fills that need.”^[] She said the drug showed “good separation from the placebo, but also from deucravacitinib, as early as week 4.” 

Hazal Jafari, MD, a board-certified dermatologist, tells MDLinx, “It's always interesting to have another oral option, especially around that path, for patients who do not like injections or do not do well with injections.”

Adverse events

Although there are no listed contraindications to icotrokinra in the label for Icotyde, the main warnings involve infection risk, TB assessment based on clinical judgment, and avoidance of live vaccines during treatment.^[] The most common adverse reactions, each at 1% or higher, were headache, nausea, cough, fungal infection, and fatigue. The label also flags higher exposure in moderate or severe renal impairment, with advice to monitor for adverse reactions when eGFR is below 60 mL/min.

What this means for the clinic

Be alert for joint symptoms

Icotrokinra is approved for plaque psoriasis, not psoriatic arthritis (PsA). A Phase 3 PsA trial is underway, though results are not yet available.^[] So the patient whose plaques improve on a new oral agent still needs routine screening for inflammatory back pain, prolonged morning stiffness, dactylitis, enthesitis, nail disease, and swollen joints.

As Dr. Jafari puts it, “I would still pay attention to the presence of joint symptoms like stiffness, swelling, and pain that does not go away, even if the skin symptoms improve. You still need to look for psoriatic arthritis because it does not always correlate with the skin symptoms.”

Expect earlier escalation from dermatology

With dermatologists expressing enthusiasm for the oral molecule over biologicals, rheumatologists can expect many early referrals. Viktoryia Kazlouskaya, MD, a board-certified dermatologist affiliated with Mount Sinai (NYC) and the University of Pittsburgh, emphasizes the appeal of the oral formulation. “While biologics are highly effective, they can be inconvenient,” she says. “And not because injections are painful. None of my patients actually complains about needle pain. The challenge is the logistics: coordinating with the pharmacy, proper storage (often refrigeration), and the disruption of a busy schedule.”

Watch for other orals

The broader pipeline also deserves attention. Takeda’s investigational oral TYK2 inhibitor zasocitinib posted positive Phase 3 data in late 2025, with about half of treated patients reaching PASI 90 and about 30% reaching PASI 100 at week 16, according to company-reported topline results and physician interviews.^[]